4 results about "Peptostreptococcus" patented technology

This invention belongs to the fields of bioinformatics and medical testing technology, specifically relating to a combination of biomarkers related to the postoperative prognosis of colorectal cancer and their application and prediction system. This invention, through 16S rRNA gene sequencing of tumor mucosal samples from colorectal cancer patients, combined with long-term postoperative follow-up data and screening, found that *Peptostreptococcus*, *Fusobacterium*, *Bacteroides*, *Porphyromonas*, and *Prevotella* are closely related to postoperative recurrence of colorectal cancer, with an AUC of 0.81 for assessing postoperative recurrence. Based on this, this invention conducts non-targeted metabolomics analysis, finding that combining alanine glutamate, putrescine, arginine, histidine, and sebacic acid with the above microbial biomarkers can improve the AUC to 0.91, significantly enhancing accuracy, specificity, and precision. This enables prognostic stratification of recurrence-free survival in colorectal cancer patients, demonstrating higher predictive efficacy and stability.

This invention belongs to the field of biomedical and analytical technology and provides an early screening model for esophageal cancer based on oral microorganisms and a method for constructing the same. [Solution] The early screening model uses the oral microbiome, including Prevotella, Granulicatella, Rothia, Prevotellamassilia, Blautia, Abiotrophia, Peptostreptococcus, Actinomyces, Burkholderia, Akkermansia, Fudania, Kineothrix, Bacillus, Duncanella, and Eisenbergiella, as markers. By identifying non-invasive biomarkers, asymptomatic esophageal cancer patients can be detected early.

The application discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the technical field of liquid biopsy and microbiome. The cervical cancer plasma circulating microbial marker combination comprises Prevotella, Sneathia, Chlamydia trachomatis, Peptostreptococcus, Fusobacterium, Campylobacter and Haemophilus. The cervical cancer plasma circulating microbial marker combination is used for verifying cervical cancer patients and healthy people, and the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, which indicates that the cervical cancer plasma circulating microbial marker combination can effectively distinguish cervical cancer patients from healthy people, is suitable for early screening of cervical cancer, and has significant clinical screening application value.

The invention belongs to the technical field of biological medicine and analysis, and provides an esophageal cancer early screening model based on oral microorganisms combined with oral health related behavior variables and a construction method thereof. The model is the following oral cavity microbial flora and oral cavity health related behavior variables: Prevotella, Granulicalala, Rothia, Prevotella, Blauria, Abiotrophia, Peptostreptococcus, Actinomyces, Burkholderia, Akkermansia, Fudania, Kineothrix, Bacillus, Duncaniella, Eisenbergiella, and a tooth brushing frequency, and the oral cavity health related behavior variables are selected from the group consisting of the following oral cavity microbial flora and oral cavity health related behavior variables. By identifying non-invasive biomarkers in combination with oral health related behavior variables, esophageal cancer patients without symptoms in the early stage can be found.